Long Ideas - The bad news finally came for Vertex Pharmaceuticals’ (VRTX) Hepatitis C drug, Incivek, and the company responded by cutting its workforce by 15%, or 370 … Continue Reading
Read nowLong Ideas - Biogen Idec (BIIB) on Monday reported third quarter revenue of $1.8 billion, an increase of 32% from last year’s third quarter, and earnings of $2.05 … Continue Reading
Read nowRecap - Medivation (MDVN) announced on Tuesday morning that the Phase III PREVAIL study, testing Xtandi (enzalutamide) in chemotherapy-naive patients with advanced prostate cancer, was stopped early … Continue Reading
Read nowLong Ideas - Medivation (MDVN) announced on Tuesday morning that the Phase III PREVAIL study, testing Xtandi (enzalutamide) in chemotherapy-naive patients with advanced prostate cancer, was stopped early … Continue Reading
Read nowLong Ideas - Tekmira Pharmaceuticals (TKMR) announced a secondary offering on Wednesday and priced the deal before Thursday’s open. Tekmira is selling 3,750,000 common stock at a price … Continue Reading
Read nowLong Ideas - Editor’s Note: A version of this commentary was sent to PropThink Premium subscribers on the morning of Thursday, October 17. On Friday the 18th, TKMR … Continue Reading
Read nowMost Popular - At PropThink, the story of the day on Friday was the sell-off in Endocyte, Inc (ECYT). Endocyte‘s lead asset is vintafolide, a folate receptor-targeting small … Continue Reading
Read now